Efficacy and safety of baricitinib in patients with active rheumatoid arthritis (RA) and inappropriate response (IR) to conventional synthetic disease modifying anti-rheumatic drugs (csDMARDS): results from the 24-week (wk) phase 3 (ph3) RA-BUILD study

Autor: Emery, P, Krogulec, M, Blanco Alonso, R, Rossini, M, Raeman, F, Walker, D, Petru Ghizdavescu, A, Irto, I, Luz Rentero, M, Casillas, M, de la Torre, I, Dougados, M, Rubbert-Roth, A

Publikováno v: 44. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh); 30. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh); 26. Jahrestagung der Gesellschaft für Kinder-und Jugendrheumatologie (GKJR); 20160831-20160903; Frankfurt am Main; DOCRA.29 /20160829/

Background: We present efficacy, safety and patient-reported outcome (PRO) analyses from patients with active RA and IR to csDMARDs in the randomised 24-wk ph3 RA-BUILD study of baricitinib, an oral JAK1/2 inhibitor. Methods: Patients with active RA

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb57d25b907d63e1c8133e498289a587

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.